[AMRN] Amarin Corporation plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.11 Change: 0.12 (4.01%)
Ext. hours: Change: 0 (0%)

chart AMRN

Refresh chart

Strongest Trends Summary For AMRN

AMRN is in the medium-term up 516% in 1 year. In the long-term up 1215% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.39% Sales Growth - Q/Q-3.32% P/E-8.88
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.56% ROE99.49% ROI-38.89%
Current Ratio4.46 Quick Ratio4.08 Long Term Debt/Equity1.49 Debt Ratio-0.69
Gross Margin63.04% Operating Margin-164.67% Net Profit Margin-103.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.3 M Cash From Investing Activities Cash From Operating Activities-12.64 M Gross Profit10.31 M
Net Profit-31.13 M Operating Profit-27.05 M Total Assets215.34 M Total Current Assets189.75 M
Total Current Liabilities42.53 M Total Debt233.48 M Total Liabilities277.16 M Total Revenue15.93 M
Technical Data
High 52 week22.98 Low 52 week2.45 Last close19.59 Last change-1.41%
RSI74.61 Average true range0.92 Beta0.5 Volume2.65 M
Simple moving average 20 days13.67% Simple moving average 50 days21.3% Simple moving average 200 days84.65%
Performance Data
Performance Week10.93% Performance Month10.49% Performance Quart13.04% Performance Half570.89%
Performance Year433.79% Performance Year-to-date43.94% Volatility daily3.7% Volatility weekly8.27%
Volatility monthly16.95% Volatility yearly58.71% Relative Volume527.59% Average Volume7.97 M
New High New Low

News

2019-03-20 20:58:34 | APRIL 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amarin Corporation plc – AMRN

2019-03-20 16:00:00 | Class Action AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC Update

2019-03-20 09:48:50 | SHAREHOLDER ALERT: MHLD AMRN INGN USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-20 09:48:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Update AKRX, AMRN & CAG

2019-03-19 19:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN

2019-03-19 16:56:15 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, SVXY, AMRN and NIO

2019-03-19 16:19:34 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

2019-03-19 10:56:32 | CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-19 10:00:00 | Class Action Update AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC

2019-03-19 06:32:00 | HLS Therapeutics Announces Vascepa® icosapent ethyl Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

2019-03-19 06:30:00 | HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease

2019-03-19 06:00:00 | Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session

2019-03-18 16:15:00 | Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels

2019-03-18 13:27:40 | Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study

2019-03-18 09:00:00 | Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

2019-03-18 09:00:00 | Vascepa® icosapent ethyl Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

2019-03-17 10:03:00 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP

2019-03-17 08:15:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN

2019-03-16 08:39:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN

2019-03-16 08:35:22 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

2019-03-15 17:25:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

2019-03-15 15:55:00 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, BRS and AMRN

2019-03-15 14:46:00 | Robbins Arroyo LLP: Amarin Corporation plc AMRN Sued for Misleading Shareholders

2019-03-14 15:25:00 | CLASS ACTION UPDATE for TYME, AMRN and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-14 15:00:00 | Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Amarin Corporation AMRN and Lead Plaintiff Deadline: April 23, 2019

2019-03-14 10:16:00 | AMRN, CAG & DPLO Bronstein, Gewirtz & Grossman, LLC Class Action Update

2019-03-14 08:15:00 | Is Amarin a No-Brainer Stock to Buy on the Dip?

2019-03-14 07:30:55 | Sarepta or Amarin: Who Is Controlling Expenses Better?

2019-03-13 15:26:24 | CLASS ACTION UPDATE for SPB, ARLO, AMRN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-13 13:32:42 | Pomerantz Law Firm Announces the Filing of a Class Action against Amarin Corporation plc and Certain Officers – AMRN

2019-03-13 11:10:08 | Sarepta and Amarin: What to Expect from Their EPS Growth

2019-03-13 10:16:00 | AMRN, CAG & DPLO Bronstein, Gewirtz & Grossman, LLC Update

2019-03-13 10:07:15 | SHAREHOLDER ALERT: ATVI AMRN VNDA USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-13 09:40:08 | Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?

2019-03-13 08:09:00 | What Analysts Recommend for Sarepta and Amarin in March

2019-03-12 21:10:00 | SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-03-12 16:52:14 | AMRN ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Amarin Corporation plc – AMRN

2019-03-12 16:00:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, AVEO, AMRN and CVS

2019-03-12 10:14:00 | Class Action - AMRN, CAG & DPLO Bronstein, Gewirtz & Grossman, LLC

2019-03-11 17:45:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

2019-03-11 02:22:26 | Here's Why Amarin Gained 17% in February

2019-03-10 10:58:00 | SHAREHOLDER ALERT: TAP AMRN INGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-08 17:06:41 | Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Amarin Corporation plc AMRN

2019-03-08 11:00:00 | Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Amarin Corporation AMRN and Lead Plaintiff Deadline: April 23, 2019

2019-03-08 09:20:00 | CLASS ACTION UPDATE for ASTE, KHC and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-07 20:56:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN

2019-03-07 17:30:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

2019-03-07 16:10:00 | AMARIN CORPORATION PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Amarin Corporation plc

2019-03-07 11:45:08 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MU, SVXY, KHC and AMRN

2019-03-06 22:15:06 | Amarin Corp Plc AMRN President and CEO John F Thero Sold $5.3 million of Shares